Autoimmune Psychosis Market: Epidemiology, Therapies, Companies, DelveInsight | Hoffmann-La Roche, Arialys Therapeutics

Autoimmune Psychosis emerging therapies, such as ENSPRYNG (satralizumab, RG6168), ART5803, and others, are expected to boost the Autoimmune Psychosis Market in the upcoming years.

DelveInsight has launched a new report on "Autoimmune Psychosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Autoimmune Psychosis, historical and forecasted epidemiology as well as the Autoimmune Psychosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Autoimmune Psychosis market report @ https://www.delveinsight.com/report-store/autoimmune-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Autoimmune Psychosis Market Report:

The Autoimmune Psychosis market in the 7MM was valued at approximately USD 6.07 million in 2023 and is expected to grow throughout the forecast period (2024-2034). According to DelveInsight, there were around 561 diagnosed prevalent cases of autoimmune psychosis in the 7MM in 2023. The United States accounted for 38.9% of these cases, while EU4 and the UK combined for nearly 39.5%, and Japan represented 21.5%.
The market is anticipated to experience steady growth, driven by a strong compound annual growth rate (CAGR) from 2024 to 2034. This expansion will be fueled by the introduction of new therapies like satralizumab (RG-6168) and ART5803. Additionally, the rising prevalence of autoimmune psychosis, due to increased awareness and risk factors such as autoimmune diseases and substance abuse, will further contribute to market growth.
DelveInsight estimates that the autoimmune psychosis market in the 7MM will continue to expand at a CAGR of 18.6% from 2024 to 2034. Despite this, the treatment landscape remains underdeveloped, with no FDA-approved therapies available. Current treatments offer limited symptom relief and significant side effects, highlighting the critical need for targeted therapies to improve outcomes and reduce relapses.
Hoffmann-La Roche and Arialys Therapeutics are advancing their therapies through various stages of development, contributing to innovation in the autoimmune psychosis market. Roche's ENSPRYNG (satralizumab), an emerging therapy, is currently in Phase III clinical trials, and Roche plans to submit a regulatory filing by 2026 for its potential use in treating autoimmune encephalitis.
In 2023, there were an estimated 84,441 diagnosed cases of autoimmune encephalitis across the 7MM, with this number expected to increase by 2034. In the US alone, approximately 30,123 cases of autoimmune encephalitis with neuronal surface antigens were recorded in 2023, a figure projected to rise by 2034. The breakdown of antibody-specific autoimmune encephalitis cases in the US in 2023 includes: 4,362 cases of anti-NMDAR, 10,359 cases of anti-LGI1, 1,227 cases of anti-CASPR2, 409 cases of anti-GABAbR, 3,135 cases of anti-GAD, and 10,632 cases associated with other antibodies (such as GFAP, ANNA-2, unclassified antibodies, CRMP5, etc.).
Arialys Therapeutics has initiated a Phase 1 clinical trial for ART5803, a precision medicine designed to block disease-causing autoantibodies rather than broadly suppressing the immune system. This approach aims to provide a more targeted treatment for autoimmune neuropsychiatric diseases, including autoimmune psychosis. The first participants were dosed in October 2024, marking a significant step toward developing a specific therapy for this condition .​
In early 2024, Onyx Middleton, an 18-year-old college freshman, was initially misdiagnosed with schizophrenia due to symptoms like psychosis and seizures. After extensive testing, she was found to have anti-NMDA receptor encephalitis, a rare autoimmune disorder affecting the brain. Her case underscores the importance of considering autoimmune psychosis in differential diagnoses, especially when psychiatric symptoms are present without clear neurological signs .​
Key Autoimmune Psychosis companies such as Hoffmann-La Roche, Arialys Therapeutics, and others are evaluating new drugs for Autoimmune Psychosis to improve the treatment landscape.
Promising Autoimmune Psychosis therapies include ENSPRYNG (satralizumab, RG6168), ART5803, and others.

Autoimmune Psychosis Overview

Autoimmune psychosis is defined by the presence of isolated psychotic symptoms, often with few or no neurological signs, in patients who test positive for antibodies targeting neuronal membrane receptors, such as N-methyl-D-aspartate receptors (NMDAR), leucine-rich glioma-inactivated 1 (LGI1), and gamma-aminobutyric acid type A receptor (GABA-A). In particular, antibodies targeting NMDAR interfere with neurotransmission, leading to symptoms of psychosis and encephalitis. While these cases are commonly seen as atypical or mild forms of autoimmune encephalitis, some experts argue that their unique characteristics warrant classification as a distinct condition, known as autoimmune psychosis. This condition is classified into possible, probable, or definitive categories.

Key risk factors for autoimmune psychosis include immune system dysfunction, genetic susceptibility, and the presence of other autoimmune diseases such as lupus and multiple sclerosis. These factors underscore the importance of antibody screening in cases of psychosis that are resistant to treatment.

Symptoms of autoimmune psychosis may include hallucinations, delusions, agitation, aggression, slow cognitive processing, and anxiety, among others.


Autoimmune Psychosis Market Outlook

Autoimmune psychosis is characterized by isolated psychotic symptoms, often with few or no neurological signs, in patients who test positive for neuronal autoantibodies, particularly those targeting N-methyl-D-aspartate receptors (NMDAR). While these cases are commonly viewed as atypical or mild forms of autoimmune encephalitis, some experts argue that their unique features warrant classification as a separate condition, autoimmune psychosis. Diagnosis typically involves tests such as MRI, electroencephalogram, blood serology, and lumbar puncture.

Currently, no treatments are specifically approved for autoimmune psychosis, and management generally involves off-label immune therapies. These may include immunosuppressive treatments such as steroids, plasma exchange, intravenous immunoglobulins, and cyclophosphamide.

The pipeline for autoimmune psychosis therapies is limited, with satralizumab (RG-6168) and ART5803 being the main candidates. There is a significant unmet need for targeted treatments, as existing therapies mainly focus on symptom management rather than addressing the root cause of the condition.

Discover how the Autoimmune Psychosis market is rising in the coming years @ https://www.delveinsight.com/sample-request/autoimmune-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Autoimmune Psychosis Emerging Drugs
ENSPRYNG (satralizumab, RG6168): Hoffmann-La Roche (Chugai Pharmaceutical)
ART5803: Arialys Therapeutics/Nucleus Network

Scope of the Autoimmune Psychosis Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Autoimmune Psychosis Companies: Hoffmann-La Roche, Arialys Therapeutics, and others
Key Autoimmune Psychosis Therapies: ENSPRYNG (satralizumab, RG6168), ART5803, and others
Autoimmune Psychosis Therapeutic Assessment: Autoimmune Psychosis current marketed and Autoimmune Psychosis emerging therapies
Autoimmune Psychosis Market Dynamics: Autoimmune Psychosis market drivers and Autoimmune Psychosis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Autoimmune Psychosis Unmet Needs, KOL's views, Analyst's views, Autoimmune Psychosis Market Access and Reimbursement

To know what's more in our Autoimmune Psychosis report, visit https://www.delveinsight.com/report-store/autoimmune-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Autoimmune Psychosis Market Report:
Autoimmune Psychosis market report covers a descriptive overview and comprehensive insight of the Autoimmune Psychosis Epidemiology and Autoimmune Psychosis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Autoimmune Psychosis market report provides insights into the current and emerging therapies.
The Autoimmune Psychosis market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Autoimmune Psychosis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Autoimmune Psychosis market.

Got queries? Click here to know more about the Autoimmune Psychosis market Landscape https://www.delveinsight.com/sample-request/autoimmune-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Autoimmune Psychosis Patient Share (%) Overview at a Glance
5. Autoimmune Psychosis Market Overview at a Glance
6. Autoimmune Psychosis Disease Background and Overview
7. Autoimmune Psychosis Epidemiology and Patient Population
8. Country-Specific Patient Population of Autoimmune Psychosis
9. Autoimmune Psychosis Current Treatment and Medical Practices
10. Unmet Needs
11. Autoimmune Psychosis Emerging Therapies
12. Autoimmune Psychosis Market Outlook
13. Country-Wise Autoimmune Psychosis Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Autoimmune Psychosis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Autoimmune Psychosis Market Outlook 2034 https://www.delveinsight.com/report-store/autoimmune-psychosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Autoimmune Psychosis Pipeline Insights, DelveInsight

"Autoimmune Psychosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Autoimmune Psychosis market. A detailed picture of the Autoimmune Psychosis pipeline landscape is provided, which includes the disease overview and Autoimmune Psychosis treatment guidelines.

Contact Info:

Kritika Rehani, Team Leader Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.